Relief Therapeutics Holding AG (RLFTF)

[elllk]

In fact, that section is what left me unsure about the formulation of Aviptadil. It says "...a natural agonist that acts on both VPAC1 and VPAC2 receptors may present interesting advantages over selective VPAC2 agonists by having a more complete spectrum of action, on immune and lung cells." It was not clear to me whether a natural agonist was being added to synthetic VIP or it was referring to VIP as the natural agonist. The latter seems like strange phrasing but it may be a matter if definition. Elsewhere the following is stated "Relief also holds a  patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100." It would seem to be the case that different formulations of RLF100 have to refer to different properties being added to the synthetic VIP and not that there are different formulations of synthetic VIP.